Curis (CRIS) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings or view top-rated stocks.

2 equities research analysts have issued 12 month price objectives for Curis' shares. Their CRIS share price forecasts range from $60.00 to $120.00. On average, they expect the company's share price to reach $90.00 in the next twelve months. This suggests a possible upside of 1,351.6% from the stock's current price.
View analysts price targets for CRIS or view top-rated stocks among Wall Street analysts.

Curis' stock was trading at $11.00 at the beginning of the year. Since then, CRIS stock has decreased by 43.6% and is now trading at $6.1999.
View the best growth stocks for 2023 here.

Curis saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,330,000 shares, an increase of 14.7% from the August 31st total of 1,160,000 shares. Based on an average trading volume of 324,500 shares, the short-interest ratio is presently 4.1 days.
View Curis' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CRIS earnings forecast.

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($2.40). The biotechnology company earned $2.20 million during the quarter, compared to analysts' expectations of $2.57 million. Curis had a negative trailing twelve-month return on equity of 116.63% and a negative net margin of 471.71%.

Shares of Curis reverse split on the morning of Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRIS stock can currently be purchased for approximately $6.20.

Curis (NASDAQ:CRIS) has a market capitalization of $36.52 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis.

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.